Gordon Campbell | Parliament TV | Parliament Today | News Video | Crime | Employers | Housing | Immigration | Legal | Local Govt. | Maori | Welfare | Unions | Youth | Search

 


Hospital Supply in Jeopardy as negotiations stall

AstraZeneca Media Statement

31 July 2007

Hospital Supply in Jeopardy as Betaloc® CR and Plendil® negotiations stall

PHARMAC’s decision to issue a media statement about the ongoing negotiations with AstraZeneca over Betaloc CR and Plendil ER has confirmed AstraZeneca’s fear that negotiations with PHARMAC have broken down.

Three years ago AstraZeneca negotiated fixed term supply agreements for Betaloc CR and Plendil ER at price levels that are significantly lower than those offered in other markets (40 to 70 percent lower than other established markets). The fixed terms for Plendil ER and Betaloc CR ended on 30 June this year.

For six months AstraZeneca has been trying to negotiate a new agreement that would ensure the long term supply of Betaloc CR and Plendil for New Zealand cardiovascular patients.

Throughout the process AstraZeneca has remained committed to negotiating a successful outcome for patients. As late as 28 June AstraZeneca made an alternative proposal for the supply of a bundle of products, including Betaloc CR and Plendil ER. This proposal:

• ensures PHARMAC makes savings equivalent to the savings it would make by introducing a generic version of Betaloc CR

• gives long term commercial certainty for AstraZeneca

• creates an environment where AstraZeneca and the supplier of the generic version of Betaloc can compete fairly for market share

• creates a more certain scenario for the patient, with certainty of the same medicine.

AstraZeneca’s first indication that negotiations had stalled came when PHARMAC chose not to formally respond to the latest bundled offer and instead sent a letter to doctors on 18 July stating that further negotiations are unlikely to achieve a result. This fear was confirmed last night when PHARMAC issued a media release accusing AstraZeneca of anti-competitive behaviour.

AstraZeneca remains happy to compete with generic suppliers of Pharmaceuticals on a level playing field and does so in a number of therapeutic areas. PHARMAC’s decision to offer a supplier of a generic version of Betaloc a long term agreement but not continue negotiations with AstraZeneca is not consistent with a competitive market.

Therefore, despite its commitment to continue negotiating, AstraZeneca has been forced to consider the commercial implications of PHARMAC’s decision.

A loss of ability to compete against a generic supplier for the majority of the Betaloc business – Betaloc CR – risks the supply of the low price/low volume service item Betaloc IV. PHARMAC has been repeatedly informed, as early as December 2003 and as recently as 23 May 2007, that loss of the Betaloc CR tablet business to a generic competitor would jeopardise supply of Betaloc IV. It is estimated that current stocks of Betaloc IV will be exhausted by the end of August 2007 at the latest.

AstraZeneca remains committed to a successful negotiated resolution to the current solution regarding Betaloc and Plendil ER.

Betaloc IV is used in the initial 24-48 hours post-heart attack period to stabilise the heart or to quickly bring down the heart rate in cases of arrhythmias (irregular heart beats). In an injectable form the medication penetrates quickly in the blood stream & produces its protective effect on the heart faster than with a tablet. This speed is critical in patients suffering from a heart attack. Approximately 3500 patients use Betaloc IV annually.

Ends

For more information please contact Daniel Herd, 09 354 0577 or 027 694 3574

Summary of Products

Betaloc belongs to a group of medicines called beta-blockers. It works by affecting the body's response to some nerve impulses, especially in the heart. As a result, it decreases the heart's need for blood and oxygen and therefore reduces the amount of work the heart has to do. It also widens the blood vessels in the body, as well as helping the heart to beat more regularly.

Betaloc CR tablets1

(Metoprolol succinate controlled release tablets)

Betaloc CR is a controlled release tablet that releases its drug content in a time controlled manner. Controlled release tablets ensure a more even effect over 24 hours.

Betaloc CR tablets are used for:

• lowering high blood pressure, also called hypertension, and to reduce the risk of complications due to high blood pressure such as stroke, heart attack or early death.

• preventing angina (heart or chest pain brought on by stress or exercise in patients with coronary heart disease).

• treating or preventing heart attacks, or to reduce your risk of heart complications following a heart attack.

• treating heart failure (symptomatic mild to severe chronic heart failure in addition to other heart failure medicine), to help increase survival, reduce hospitalisation, improve symptoms, and Quality of Life.

• treating disturbances of heart rate in patients with heart disease, especially rapid heart beat.

• treating symptoms of rapid or irregular heart beat in patients without heart disease.

Betaloc IV2

(Metoprolol tartrate 1 mg/mL injection)

Betaloc IV is approved for use in:

• Cardiac arrhythmias, especially supraventricular tachycardia, reduction of ventricular rate in atrial fibrillation and ventricular extrasystoles.

• Suspected or definite myocardial infarction.

Plendil ER tablets3

(Felodipine tablets)

Plendil ER belongs to a family of medicines called calcium channel blockers. These medicines do not change the way that the body takes in calcium from food.

Plendil ER works by dilating (expanding) small blood vessels, so that blood can be pumped around the body more easily. It has no negative affect on heart function.

The ER in Plendil ER stands for Extended Release. This means that the tablets are designed to work over a 24 hour period

Plendil ER is used to treat high blood pressure (hypertension) and heart and chest pain brought on, for example, by exercise or stress (known as angina pectoris).

ends


© Scoop Media

 
 
 
 
 
Parliament Headlines | Politics Headlines | Regional Headlines

Last Sitting Day Of Parliament: Slave Ships Bill To Pass

The House resumed at 9am and MPs agreed to add the third reading of the Fisheries (Foreign Charter Vessels and Other Matters) Amendment Bill to this morning’s business.

The bill requires all foreign owned fishing vessels to fly under a New Zealand flag from May 2016 and obey all New Zealand laws. This includes labour laws...

Last night Opposition MPs accused the Maori Party of blocking the passage of this bill into law in this Parliament, no members of the Maori Party were in the House to answer the accusations though they denied this in a press release. More>>

 

Parliament Today:

Novopayout: Government-Owned Company To Take Over School Payroll

After lengthy negotiations, the Ministry of Education and the existing school payroll provider, Talent2, have settled both on the amounts payable by Talent2 towards the costs of remediating the Novopay service and a new operating model for the school payroll system. More>>

ALSO:

Employment: Labour Will Raise Minimum Wage, Restore Work Rights

A Labour government will raise the minimum wage $2 an hour to $16.25 and restore work rights to ensure the benefits of economic growth are shared fairly by all New Zealanders, Labour Leader David Cunliffe says. More>>

ALSO:

Police: Crewe File Review Released

No new evidence has come to light implicating any specific person as being responsible for the murders of Jeannette and Harvey Crewe... The review identifies there is a distinct possibility that Exhibit 350 (the brass .22 cartridge case) may be fabricated evidence, and that if this is the case, that a member of Police would have been responsible. More>>

ALSO:

Werewolf Issue #49: Gordon Campbell Interviews Laila Harre

For 25 years, Labour and National have been in virtual agreement about the basics of economic policy, and differed mainly on how to go about managing its social consequences. More>>

ALSO:

Greens: Plan To Protect Our Maui’s Dolphins

1. Protect Maui’s from being killed in the sanctuary set up to protect them... 2. Extend fishing protections to the entire Maui’s range... 3. Help protect the livelihoods of affected fishers by supporting them to adopt dolphin-safe fishing methods. More>>

ALSO:

Gordon Campbell: On National’s Electorate Deals

For all the talk yesterday from Prime Minister John Key about National being transparent about its electorate deals in Epsom and Ohariu, that transparency is entirely front-loaded. More>>

ALSO:

Greens: Oil Drilling Face-Off With Labour

The key policy points in the Green Party’s plan to protect our beaches from oil spills are to:
1. Prohibit deep sea oil drilling; 2. Implement compulsory shipping lanes for coastal shipping; 3. Build Maritime New Zealand’s oil spill response capability; and 4. Introduce a stronger legal framework so that when accidents do happen, the New Zealand taxpayer does not have to pay for the clean-up. More>>

ALSO:


Nick Smith v Fish & Game:

Get More From Scoop

 

LATEST HEADLINES

 
 
 
 
 
 
Politics
Search Scoop  
 
 
Powered by Vodafone
NZ independent news